CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy.
CD44, a cancer stem cell (CSC)-related surface marker, correlates with local control after radiotherapy of early laryngeal cancer. For the first time, a CSC-related marker has been functionally validated for radiotherapy in patients. CD44 expression bears the potential to predict the outcome of radiotherapy by assessment of CSC density.
Baumann
Michael
M
Department of Radiation Oncology and OncoRay Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. Michael.Baumann@uniklinikum-dresden.de
Krause
Mechthild
M
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy*; D015972:Gene Expression Regulation, Neoplastic / Q000528:radiation effects; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000378:metabolism* / Q000528:radiation effects; D011379:Prognosis
D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors